Wanbury Strengthens Coriminic Brand with Pediatric-Focused Launches
Wanbury Limited announced new product launches aimed at bolstering its Coriminic brand for children experiencing cold and sneezing. The launches include Coriminic CPM Drops (Chlorpheniramine Maleate) and Coriminic NS (Normal Saline) Nasal Drops.The move comes in response to recent advisories and regulatory restrictions issued by the Drugs Controller General of India (DCGI), which have limited the use of fixed-dose combinations containing Chlorpheniramine + Phenylephrine in children under 4 years of age. Coriminic CPM Drops is designed to address this restriction by providing Chlorpheniramine Maleate without a decongestant. Coriminic NS Nasal Drops offer localized relief from nasal congestion.
Wanbury aims to capture a significant share of the 861 crore Cold Preparation Liquid market with this expansion. Coriminic CPM Drops offers targeted relief from allergic symptoms, including severe cold, blocked nose, and sneezing, while aligning with current regulatory guidance and promoting rational prescribing practices.
This initiative is a first-of-its-kind effort in India to reposition Chlorpheniramine in a safer, indication-driven format for pediatric use. Wanbury Limited focuses on providing affordable healthcare solutions across therapeutic segments, including pediatrics.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.